Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 EV-to-EBITDA is 39.36 as of Sep. 01, 2026, which is 10% above its 10-year median of 35.70. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 121 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks worse than 80.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, WuXi XDC Cayman's enterprise value is €9,119.2 Mil.
WuXi XDC Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €231.7 Mil. Therefore, WuXi XDC Cayman's EV-to-EBITDA for today is 39.36.
The historical rank and industry rank for WuXi XDC Cayman's EV-to-EBITDA or its related term are showing as below:
STU:L74'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 22.59 Med: 35.7 Max: 150.69
Current: 39.44
During the past 6 years, the highest EV-to-EBITDA of WuXi XDC Cayman was 150.69. The lowest was 22.59. And the median was 35.70.
STU:L74's EV-to-EBITDA is ranked worse than 80.17% of 121
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.24
vs STU:L74: 39.44
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WuXi XDC Cayman's PE Ratio (TTM) for today is calculated as:
WuXi XDC Cayman's share price for today is €7.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.144.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for WuXi XDC Cayman's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L74 vs TMO, DHR, NTRA: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's EV-to-EBITDA falls into.
WuXi XDC Cayman's current Enterprise Value is €9,119.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi XDC Cayman's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €231.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (STU:L74) has a EV-to-EBITDA of 39.36 as of Sep. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WuXi XDC Cayman. This is 10% above median its historical median of 35.70. Over the past decade, WuXi XDC Cayman's EV-to-EBITDA has ranged from 22.59 to 150.69. According to the industry distribution chart, WuXi XDC Cayman ranks #97 out of 121 companies in the Medical Diagnostics & Research industry, placing it in the top 80.2%.
Is WuXi XDC Cayman's EV-to-EBITDA too high?
WuXi XDC Cayman's current EV-to-EBITDA of 39.36 is 10% above median its 10-year median of 35.70. Over the past 10 years, this metric has ranged from a low of 22.59 to a high of 150.69. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.24. WuXi XDC Cayman's value of 39.36 is 142.4% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #97 out of 121 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #97 out of 121 companies for EV-to-EBITDA. This places WuXi XDC Cayman in the lower half of its industry. The industry median EV-to-EBITDA is 16.24. WuXi XDC Cayman's value of 39.36 is 142.4% above this benchmark. Historically, WuXi XDC Cayman's own EV-to-EBITDA has ranged from 22.59 to 150.69 over the past decade. While the company's 10-year median is 35.70 vs. the industry median of 16.24, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.24, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current EV-to-EBITDA of 39.36 is 142.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on WuXi XDC Cayman. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EV-to-EBITDA is 39.36, which is 10% above median its own 10-year median of 35.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current EV-to-EBITDA of 39.36. The current EV-to-EBITDA is 39.36, which is 10% above median its 10-year median of 35.70 and 142.4% above the Medical Diagnostics & Research industry median of 16.24. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current EV-to-EBITDA is 39.36 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
